Your browser doesn't support javascript.
loading
Wait-and-scan management in sporadic Koos grade 4 vestibular schwannomas: A longitudinal volumetric study.
Schouten, Sammy M; Cornelissen, Stefan; Langenhuizen, Patrick P H J; Jansen, Thijs T G; Mulder, Jef J S; Derks, Jolanda; Verheul, Jeroen B; Kunst, Henricus P M.
Afiliação
  • Schouten SM; Department of Otolaryngology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Cornelissen S; Department of Otolaryngology, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Langenhuizen PPHJ; Dutch Academic Alliance Skull Base Pathology Radboudumc/MUMC+, Nijmegen and Maastricht, The Netherlands.
  • Jansen TTG; Gamma Knife Center, Department of Neurosurgery, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
  • Mulder JJS; Gamma Knife Center, Department of Neurosurgery, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
  • Derks J; Eindhoven University of Technology, Eindhoven, The Netherlands.
  • Verheul JB; Gamma Knife Center, Department of Neurosurgery, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
  • Kunst HPM; Eindhoven University of Technology, Eindhoven, The Netherlands.
Neurooncol Adv ; 6(1): vdad144, 2024.
Article em En | MEDLINE | ID: mdl-38187870
ABSTRACT

Background:

Volumetric natural history studies specifically on large vestibular schwannomas (VSs), commonly classified as Koos grade 4, are lacking. The aim of the current study is to present the volumetric tumor evolution in sporadic Koos grade 4 VSs and possible predictors for tumor growth.

Methods:

Volumetric tumor measurements and tumor evolution patterns from serial MRI studies were analyzed from selected consecutive patients with Koos grade 4 VS undergoing initial wait-and-scan management between January 2001 and July 2020. The significant volumetric threshold was defined as a change in volume of ≥10%.

Results:

Among 215 tumors with a median size (IQR) of 2.7 cm3 (1.8-4.2), 147 tumors (68%) demonstrated growth and 75 tumors (35%) demonstrated shrinkage during follow-up. Growth-free survival rates (95% CI) at 1, 2, 5, and 10 years were 55% (48-61), 36% (29-42), 29% (23-36), and 28% (21-34), respectively and did not significantly differ in tumors> 20 mm (Chi-square = .40; P-value = .53). Four tumor evolution patterns (% of total) were observed continued growth (60); initial growth then shrinkage (7); continued shrinkage (27); and stability (5). Good hearing (adjusted HR 2.21, 95% CI 1.48-3.30; P < .001) and peritumoral edema (adjusted HR 2.22, 95% CI 1.18-4.13; P = .01) at diagnosis were significantly associated with an increased likelihood of growth.

Conclusions:

Koos grade 4 VSs show a wide variety in size and growth. Due to variable growth patterns, an initial wait-and-scan strategy with short scan intervals may be an acceptable option in selected tumors, if no significant clinical symptoms of mass effect that warrant treatment are present.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Neurooncol Adv Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Neurooncol Adv Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda